News
Novo turns to Hengrui for another oral obesity drug
Novo has agreed to pay up to $2.6 billion for rights to a weight-loss pill, developed by China's Hengrui Pharma, that could be dosed just once a week.
News
Mirum puts Hepcludex in its sights with hep D readout
Gilead's Hepcludex was the first drug to be cleared in the US for hepatitis D in May, but a potential rival from Mirum Pharma is already looming.
News
AZ takes stake in Summit Therapeutics in $2bn deal
AstraZeneca has taken a roughly 10% stake in Summit and signed a deal to test CLDN18.2-targeting sone-ve with PD-1xVEGF bispecific ivonescimab.
R&D
Why every healthcare breakthrough creates a new education ch...
Patients will only benefit from a health breakthrough if HCPs and the systems around them are able to put it into practice.
News
Roche culls myostatin candidate from obesity pipeline
Roche has abandoned the development of one of its obesity candidates, emugrobart, and returned rights to originator Chugai Pharma.
Debates & Insights
News
Press Releases
Editor's Picks
Editor's Picks
